Top Page
Shanghai Junshi Biosciences Co., Ltd. Class H
(1877)
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Junshi Biosciences Co., Ltd. Class H Business Overview & Revenue Model
Shanghai Junshi Biosciences Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.54B | 1.95B | 1.50B | 1.45B | 4.02B | 1.59B |
| Gross Profit | 2.08B | 1.54B | 835.26M | 927.21M | 2.77B | 1.22B |
| EBITDA | -745.31M | -935.50M | -2.16B | -2.52B | -476.32M | -1.58B |
| Net Income | -966.82M | -1.28B | -2.28B | -2.39B | -718.56M | -1.67B |
Balance Sheet | ||||||
| Total Assets | 12.77B | 10.80B | 11.36B | 12.58B | 11.05B | 8.01B |
| Cash, Cash Equivalents and Short-Term Investments | 3.57B | 2.93B | 3.78B | 6.00B | 3.50B | 3.39B |
| Total Debt | 3.92B | 2.93B | 1.79B | 1.32B | 628.20M | 850.78M |
| Total Liabilities | 5.89B | 4.85B | 4.02B | 2.78B | 2.72B | 2.17B |
| Stockholders Equity | 6.79B | 5.86B | 7.17B | 9.50B | 7.96B | 5.84B |
Cash Flow | ||||||
| Free Cash Flow | -1.28B | -2.12B | -2.85B | -2.17B | -1.53B | -2.09B |
| Operating Cash Flow | -681.74M | -1.43B | -2.01B | -1.78B | -641.90M | -1.50B |
| Investing Cash Flow | -745.27M | -892.78M | -892.42M | -467.62M | -1.88B | -697.98M |
| Financing Cash Flow | 1.70B | 1.02B | 681.04M | 4.64B | 2.67B | 4.41B |
Shanghai Junshi Biosciences Co., Ltd. Class H Technical Analysis
Shanghai Junshi Biosciences Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$32.96B | 36.97 | 27.37% | ― | 2.57% | 18.79% | |
53 Neutral | HK$9.97B | 40.68 | 13.34% | ― | 206.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$20.98B | -14.30 | -161.12% | ― | -56.94% | -190.36% | |
42 Neutral | HK$15.05B | -9.08 | -30.41% | ― | 23.87% | 30.08% | |
40 Neutral | HK$47.89B | -40.63 | -39.64% | ― | 46.14% | 39.56% | |
38 Underperform | HK$36.45B | -21.91 | -15.06% | ― | 38.56% | 48.26% |
Shanghai Junshi Biosciences Co., Ltd. Class H Corporate Events
Shanghai Junshi Biosciences Co., Ltd. announced that two new indications for its products, Toripalimab Injection (TUOYI) and Ongericimab Injection (JUNSHIDA), have been added to China’s National Reimbursement Drug List (NRDL) effective January 2026. This inclusion marks a significant milestone for the company, as all 12 indications of TUOYI are now covered, making it the only anti-PD-1 monoclonal antibody in the NRDL for renal cancer, TNBC, and melanoma. JUNSHIDA’s inclusion is notable as it is the only domestic PCSK9-targeted drug for statin-intolerant patients in the NRDL, enhancing the company’s market positioning and potential stakeholder benefits.
Shanghai Junshi Biosciences Co., Ltd. announced the acceptance of its new drug application for Roconkibart Injection by the National Medical Products Administration. This drug, aimed at treating moderate to severe plaque psoriasis, has shown significant efficacy in clinical trials and represents a potential advancement in the treatment of autoimmune diseases, enhancing the company’s position in the pharmaceutical industry.
Shanghai Junshi Biosciences Co., Ltd. announced a reduction in shareholding by Shanghai Tanying Investment Partnership, which previously held over 6.96% of the company’s total share capital. This decision follows the maturity of the fund and liquidity arrangements, impacting the company’s shareholder structure and potentially influencing market perceptions of its financial strategy.
Shanghai Junshi Biosciences Co., Ltd. announced a change in equity holdings, with shareholders holding more than 5% of shares reducing their stake from 5.0051% to 4.7129%. This change does not breach any commitments or trigger a mandatory tender offer obligation, indicating a strategic adjustment in shareholder composition without significant operational impact.
Shanghai Junshi Biosciences Co., Ltd. has announced a new cash management strategy involving the use of temporarily idle proceeds to purchase principal guaranteed investment products with high security and good liquidity. This move aims to improve the efficiency of fund utilization without affecting the company’s ongoing investment plans, and it has been approved by the Board of Directors, with a validity of 12 months.
Shanghai Junshi Biosciences Co., Ltd. announced that its phase III clinical study of JS001sc, a subcutaneous injection formulation for the first-line treatment of non-squamous non-small cell lung cancer (NSCLC), has met its primary endpoints. This development marks a significant step in providing a more convenient administration method for immunotherapy, potentially enhancing patient experience and positioning the company as a leader in domestic anti-PD-1 monoclonal antibody treatments. The company plans to submit a new drug application to regulatory authorities, which could impact its market presence and offer new options for NSCLC patients.
Shanghai Junshi Biosciences Co., Ltd. has completed the registration of its First Grant of A Share Options under the 2025 A Share Option Incentive Scheme, following shareholder approval. The scheme involves 24,700,000 A Share Options granted to 226 participants, including employees and a substantial shareholder, with specific vesting and exercise conditions outlined for the options. This initiative is expected to enhance stakeholder engagement and align employee interests with company growth objectives.
Shanghai Junshi Biosciences Co., Ltd. announced that its chairman, Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB100 million, with a minimum of RMB50 million allocated to A shares. As of the announcement date, Mr. Xiong Jun has already acquired 100,000 A shares, representing 0.01% of the company’s total share capital, through the Shanghai Stock Exchange. This move reflects confidence in the company’s future prospects, although the plan’s completion is subject to market conditions and other unpredictable risk factors.
Shanghai Junshi Biosciences Co., Ltd. has released its unaudited financial results for the third quarter of 2025, reporting a significant increase in operating income. The company’s revenue rose by 31.40% during the reporting period and by 42.06% from the beginning of the year, highlighting its strong market performance and potential positive impact on its stakeholders.
Shanghai Junshi Biosciences Co., Ltd. announced that its wholly-owned subsidiary, Suzhou Union Biopharm Co., Ltd., has successfully passed an unannounced FDA on-site inspection for Current Good Manufacturing Practice (CGMP) compliance. This achievement marks the second successful FDA inspection for Suzhou Union, reinforcing the company’s high production standards and supporting its expansion strategy in the U.S. market. The successful inspection is expected to positively impact the company’s operations and strengthen its position in the global pharmaceutical industry.
Shanghai Junshi Biosciences Co., Ltd. announced the convening of its 2025 third quarterly results briefing, scheduled for October 29, 2025. The briefing aims to provide investors with a comprehensive understanding of the company’s operating results and financial status for the third quarter of 2025, facilitating communication between the company and its stakeholders.
Shanghai Junshi Biosciences Co., Ltd. announced that the U.S. FDA has approved its investigational new drug application for a phase II/III clinical study of JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, for the neoadjuvant treatment of non-small cell lung cancer (NSCLC) patients. This approval marks a significant step for the company as it positions JS207 as a potential new treatment option for NSCLC, addressing unmet clinical needs and potentially improving patient outcomes in a highly prevalent and deadly cancer type.
Shanghai Junshi Biosciences Co., Ltd. has announced that its board of directors will meet on October 28, 2025, to review and approve the company’s unaudited financial results for the nine months ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and performance, potentially impacting its market positioning and stakeholder confidence.
Shanghai Junshi Biosciences Co., Ltd. announced that its chairman, Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB100 million, with a minimum of RMB50 million allocated to A shares. As of October 2025, the shareholding increase plan has reached its midpoint, but due to various factors such as reporting windows and funding arrangements, the increase has not yet been completed. Mr. Xiong Jun intends to continue with the shareholding increase plan as opportunities arise, which may impact the company’s market position and shareholder confidence.
Shanghai Junshi Biosciences Co., Ltd. announced adjustments to its 2025 A Share Option Incentive Scheme, reducing the number of participants from 251 to 235 and the total A Share Options from 26,175,871 to 25,965,871. These changes, approved by the Board of Directors and the Remuneration and Appraisal Committee, are not expected to materially impact the company’s financial condition or operations, and do not require further shareholder approval.
Shanghai Junshi Biosciences Co., Ltd. announced the election of Dr. Yang Jin as an Independent Non-executive Director, effective September 29, 2025. This change also affects the composition of the Remuneration and Appraisal Committee and the Nomination Committee, with Dr. Yang Jin and Ms. Lu Kun taking new roles. The abolishment of the Board of Supervisors marks a significant shift in the company’s governance structure, potentially impacting its operational and strategic direction.
Shanghai Junshi Biosciences Co., Ltd. announced the successful passing of all resolutions during its 2025 first extraordinary general meeting. The meeting saw significant participation from shareholders, with a notable percentage of shares represented. Key resolutions included the election of an Independent Non-executive Director and amendments to internal management policies, reflecting the company’s strategic focus on governance and operational efficiency.
Shanghai Junshi Biosciences Co., Ltd. has announced a capital increase agreement involving its non-wholly owned subsidiary, JunTop Biosciences, and Shanghai Tanying Investment Partnership. This transaction, which is classified as a related party transaction under PRC laws, does not constitute a connected transaction under Hong Kong’s Listing Rules. The agreement signifies a strategic move to bolster financial resources, potentially enhancing the company’s market position and operational capabilities.
Shanghai Junshi Biosciences Co., Ltd. has announced the composition of its board of directors and their roles within the company. This update includes the appointment of executive, non-executive, and independent non-executive directors, along with the establishment of five committees to oversee various aspects of the company’s governance and strategic direction.
Shanghai Junshi Biosciences Co., Ltd. has announced the adjournment of its 2025 first extraordinary general meeting (EGM) to 29 September 2025. The meeting will address special resolutions regarding the proposed grant of H Share Options to Mr. Zhang Zhuobing and Dr. Yao Sheng, contingent upon the adoption of the 2025 H Share Option Incentive Scheme. This development is significant for stakeholders as it reflects the company’s ongoing efforts to incentivize key personnel, potentially impacting its strategic direction and market positioning.
Shanghai Junshi Biosciences Co., Ltd. has announced the adjournment of its Extraordinary General Meeting (EGM) initially scheduled for September 26, 2025, now rescheduled to September 29, 2025. This postponement is to provide shareholders with additional time to consider special resolutions. The company has issued a supplemental proxy form and circular to guide shareholders on the new voting procedures, ensuring clarity and compliance in the decision-making process.
Shanghai Junshi Biosciences Co., Ltd. announced a change in equity holdings, where the shareholders holding more than 5% of the company’s shares, including Shanghai Tanying Investment Partnership and its concerted parties, have reduced their total equity proportion from 8.96% to 7.91%. This change does not breach any commitments or trigger a mandatory tender offer obligation, indicating a strategic adjustment in shareholder structure without significant implications for the company’s operational commitments or market positioning.
Shanghai Junshi Biosciences Co., Ltd. announced that its anti-IL-17A monoclonal antibody, JS005, has successfully met the primary and secondary endpoints in a Phase III clinical study for treating moderate to severe plaque psoriasis. This achievement marks a significant advancement in the company’s product pipeline, potentially enhancing its market position in the autoimmune disease treatment sector. The study demonstrated that JS005 significantly improved psoriasis symptoms compared to a placebo, with good safety results, and the company plans to submit a new drug application soon.